AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03832413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
Study NCT00495287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytosine arabinoside
Description: Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.
Study NCT00495287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytosine arabinoside
Description: Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.
Study NCT02661087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic resection with bipolar energy
Description: Hysteroscopic resection with bipolar energy
Study NCT02661087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic resection with monopolar energy
Description: Hysteroscopic resection with monopolar energy
Study NCT03728556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001 monoclonal antibody
Description: Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
Study NCT03728556 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CS1001 placebo
Description: Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
Study NCT01696110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin plus tirofiban
Description: combined use of heparin and tirofiban during PCI
Study NCT02896803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFLOX
Description: 5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
Study NCT02201394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose
Description: Single loading dose of Ticagrelor 180 mg
Study NCT01810120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR alfa beta T cell depletion
Description: total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
Study NCT04822285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Triaging Intervention
Description: The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).
Study NCT04822285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine psychological support
Description: For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
Study NCT00063154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab was supplied as a single-use liquid formulation.
Study NCT04685226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-723
Description: ICP-723 is a white, round, uncoated table
Study NCT04235933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tai Ai(RC18) 80mg
Description: The patient received one treatment of RC18 80mg in the test group
Study NCT04235933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tai Ai(RC18) 160mg
Description: The patient received one treatment of RC18 160mg in the test group
Study NCT04235933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240mg
Description: The patient received one treatment of RC18 240mg in the test group
Study NCT00121277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00121277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study NCT04384315 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
Study NCT04011618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ellagic Acid / Pomegranate Extract
Description: Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Study NCT04011618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Study NCT02201394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin loading dose
Description: Single loading dose of Aspirin 325 mg
Study NCT02201394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor maintenance dose
Description: Ticagrelor 90 mg twice daily x 7 days
Study NCT02201394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin maintenance dose
Description: Aspirin 81 mg once daily x 7 days
Study NCT04489836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutalytic®
Description: Glutalytic® capsule
Study NCT04489836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DE111®
Description: DE111® capsule
Study NCT04489836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal A
Description: Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
Study NCT01660048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS TEP repair
Description: perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
Study NCT01660048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total extraperitoneal inguinal hernia repair
Description: Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
Study NCT01660048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total extraperitoneal inguinal hernia repair
Description: Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
Study NCT03162263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKso training
Description: Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
Study NCT03162263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKso training
Description: Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
Study NCT02242526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex™ Composite Hiatal Mesh, North Haven, CT
Description: Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
Study NCT03794167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
Study NCT03794167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
Study NCT03794167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
Study NCT03794167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide 400mg/m2 day i.v. on days -5 and -4
Study NCT03794167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: etoposide 400mg/m2 day i.v. on days -5 and -4
Study NCT03794167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: melphalan 50mg/m2/day i.v. on days -3 and -2
Study NCT02953171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw, lacto-fermented sauerkraut
Description: Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
Study NCT02953171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mutaflor
Description: The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
Study NCT02953171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pasteurized sauerkraut
Description: Sauerkraut without live bacteria.
Study NCT02953171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized sauerkraut
Description: Sauerkraut without live bacteria.
Study NCT02953171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Capsules without probiotics
Study NCT02953171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Capsules without probiotics
Study NCT04211428 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT02782130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Epic Allies App Intervention
Description: The Epic Allies app addresses barriers to ART adherence through:~1. Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~2. Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~3. A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~4. Users progress through Epic Allies' virtual world, creating allies with other users.~5. The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy.
Study NCT02782130 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Epic Allies - Control Branch
Description: Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
Study NCT00681330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URC10, TTK, KOC1
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT03328403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration First
Description: Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
Study NCT03328403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent retriever first
Description: Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
Study NCT00104559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMIC-generated consent form and tutorial
Description: Computer-based consent form and tutorial
Study NCT00104559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard paper consent form
Description: Standard paper consent form
Study NCT04259073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
Study NCT04259073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: two capsules filled with sugar ingested orally one hour before cesarean section
Study NCT04259073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300mg
Description: two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
Study NCT01049971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wound protector
Description: after minilaparotomy, the wound protector is applied
Study NCT01049971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no wound protector
Description: use of woven drape instead of wound protector
Study NCT03434782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
Study NCT03434782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
Study NCT03434782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate / 2% sodium fluoride gel
Description: 5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
Study NCT04643288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement
Description: open flap debridement for managing two and three walls intrabony periodontal defects
Study NCT04643288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: n-HA bone graft
Description: Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
Study NCT00521560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM
Study NCT00648817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
Study NCT00648817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
Study NCT00648817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir DF placebo
Description: Tenofovir DF placebo tablet QD
Study NCT00648817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir DF placebo
Description: Tenofovir DF placebo tablet QD
Study NCT04328636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulfate
Description: Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
Study NCT04328636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Magnesium Sulfate
Description: Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
Study NCT04564651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet transfusion
Description: when the ADP inhibition >70%, give one unit platelet tansfusion
Study NCT01259726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VP20621
Description: VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
Study NCT01259726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VP20621
Description: VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
Study NCT01259726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mL placebo once daily for 14 days
Study NCT01259726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 mL placebo once daily for 14 days
Study NCT01259726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VP20621
Description: VP20621 as oral liquid once daily for 14 days
Study NCT00634660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
Study NCT01832233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
Study NCT00196404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001a
Description: 4mg daily vaginally
Study NCT00196404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001b
Description: 6 mg vaginally daily
Study NCT00196404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered vaginally to match experimental arms
Study NCT04626492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI imaging
Description: Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
Study NCT01980550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual nicotine
Description: The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
Study NCT02522455 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flow-cycle ventilation
Description: Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
Study NCT02522455 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time-cycle ventilation mode
Description: Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
Study NCT02853357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust.